Traditional treatments for kidney cancer include surgery (radical or partial nephrectomy, etc.), cytokine therapy (interferon, etc.), chemotherapy and hormone therapy. For advanced kidney cancer, these traditional treatments are currently ineffective. Although cytokine therapy plays the role of regulating immunity, it cannot directly destroy tumor cells, while chemotherapy and hormone therapy have been proven to be usually ineffective for renal cell carcinoma. With the development and advancement of technology, targeted therapy is to target certain unique signaling pathways in the pathogenesis of tumors and use small molecules to interfere with these pathways, thus greatly improving its efficiency in inhibiting tumor cell growth and achieving the purpose of tumor control and elimination. Targeted therapies represented by sunitinib (Sotan) and sorafenib (Doxorubicin) can shrink kidney cancer lesions by simultaneously inhibiting both tumor cell proliferation and tumor angiogenesis. More than 130,0002 million kidney cancer patients worldwide have benefited from treatment with sunitinib and sorafenib, which have become the standard of care for advanced kidney cancer.